Added to YB: 2025-12-23
Pitch date: 2025-12-19
SCLP.L [neutral]
Scancell Holdings plc
-1%
current return
Author Info
Increasing Odds shares their investment journey in their newsletter. Sign up for the newsletter.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom.
Market Cap
GBP 103.8M
Pitch Price
GBP 0.10
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.30
P/E
-7.91
EV/Sales
21.90
Sector
Biotechnology
Category
N/A
Show full summary:
AIM A-Z Part 29: NAV Discounts, Gold and an Ex-Fintwit-Favourite - Pass: Scancell Holdings plc
SCLP.L (pass): £106m clinical-stage cancer biotech, highly unprofitable. Only revenue from Danish partnership licensing SCLP's antibodies for £6m total (£1m upfront). No expected royalty income currently.
Read full article (1 min)